Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

CIP2A drives lung adenocarcinoma by activating mitochondrial respiratory complexes IV and V.

Created on 12 Nov 2026

Authors

Fu-Ying Yang, Di Wang, Liu Ye, Yi-Meng Zhang, Li-Jun Liang, Yan-Fei Zhang, Yi-Shuai Tan, Aikede Alifu, Meng-Yao Lv, Fen-Rong Xie, Yan-Yun Gao, Jiao-Jiao Xu, Yang-Tong Liu, Cong Wang, Bing-Qing Xu, Yan-Zhi Bai, Zhi-Xiao Liao, Yu-Tao Liu, Gui-Zhen Wang, Guang-Biao Zhou

Published in

Cancer letters. Pages 218967. Nov 11, 2026. Epub Nov 11, 2026.

Abstract

To determine the cancer-initiating activity of oncoprotein CIP2A, which is overexpressed in a majority of cancers and promotes cell growth by stabilizing MYC, we established an alveolar type 2 cell-specific CIP2A transgenic mouse line. Among 114 transgenic mice aged 12 months or older, 23 (20.2%) developed lung adenocarcinoma (LUAD)-like disease, significantly higher than in the control mice (3/63, 4.8%). Multi-omic studies revealed enrichment of the oxidative phosphorylation (OXPHOS) pathway in tumor tissues from transgenic mice. CIP2A upregulated phosphorylation of FOXO3A (p-FOXO3A S253) by inhibiting phosphatase PP2A-B56α and promoted FOXO3A mitochondrial translocation. CIP2A-FOXO3A reshaped mitochondrial morphology, activated mitochondrial DNA transcription, and enhanced complexes IV/V activities. OXPHOS inhibitor repressed CIP2A-induced cell proliferation and tumor growth. Moreover, tobacco carcinogens upregulated CIP2A and p-FOXO3A S253 and significantly increased cancer incidence in CIP2A-transgenic mice. These data indicate that CIP2A plays a critical role in mitochondrial regulation and represents a promising therapeutic target for LUADs lacking actionable driver mutations.

PMID:
43014540
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement